DAPSA scores reflect both articular and cutaneous involvement in psoriatic arthritis.

Qianzi Liu, Minjia Tan, Yehong Kuang

Abstract read

In one paragraph

Article in Anais brasileiros de dermatologia. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Qianzi LiuDepartment of Dermatology, Xiangya Hospital, Central South University, Changsha, China; National Engineering Research Center of Personalized Diagnostic and Therapeutic Technology, Changsha, China; Furong Laboratory, Changsha, China; National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China; Hunan Key Laboratory of Skin Cancer and Psoriasis, Xiangya Hospital, Central South University, Changsha, China; Hunan Engineering Research Center of Skin Health and Disease, Xiangya Hospital, Central South University, Changsha, China; Xiangya Clinical Research Center for Cancer Immunotherapy, Central South University, Changsha, China.

Minjia TanDepartment of Dermatology, Xiangya Hospital, Central South University, Changsha, China; National Engineering Research Center of Personalized Diagnostic and Therapeutic Technology, Changsha, China; Furong Laboratory, Changsha, China; National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China; Hunan Key Laboratory of Skin Cancer and Psoriasis, Xiangya Hospital, Central South University, Changsha, China; Hunan Engineering Research Center of Skin Health and Disease, Xiangya Hospital, Central South University, Changsha, China; Xiangya Clinical Research Center for Cancer Immunotherapy, Central South University, Changsha, China.

Yehong KuangDepartment of Dermatology, Xiangya Hospital, Central South University, Changsha, China; National Engineering Research Center of Personalized Diagnostic and Therapeutic Technology, Changsha, China; Furong Laboratory, Changsha, China; National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China; Hunan Key Laboratory of Skin Cancer and Psoriasis, Xiangya Hospital, Central South University, Changsha, China; Hunan Engineering Research Center of Skin Health and Disease, Xiangya Hospital, Central South University, Changsha, China; Xiangya Clinical Research Center for Cancer Immunotherapy, Central South University, Changsha, China. Electronic address: yh_927@126.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe Disease Activity Index for Psoriatic Arthritis (DAPSA) is a widely used tool to assess joint involvement in Psoriatic Arthritis (PsA), but its ability to reflect skin disease severity remains unclear.

objectiveThis study aimed to investigate the association between DAPSA scores and skin disease severity in patients with PsA.

methodsThis single-center, cross-sectional study included PsA patients meeting the CASPAR classification criteria at Xiangya Hospital from April 2019 to February 2025. Skin disease severity was assessed using the Psoriasis Area and Severity Index (PASI) and Dermatology Life Quality Index (DLQI), while disease activity was assessed with the DAPSA. Propensity Score Matching (PSM) was applied to adjust for musculoskeletal disease activity.

resultsAmong the 646 PsA patients (median age 46.0 years; 41.0% male), DAPSA scores increased from 12.6 (SD = 13.2) in patients with no skin disease (PASI = 0) to 20.4 (SD = 16.9) in those with severe skin disease (PASI > 10). Patient global assessment, patient pain assessment scores and C-reactive protein levels also rose with PASI severity (all p < 0.001). After PSM, patients with PASI ≥ 10 had significantly higher DAPSA scores than those with PASI < 10 (25.4 vs. 16.9, p < 0.001). A weak but statistically significant positive correlation was observed between DAPSA and PASI scores (Spearman's rho = 0.256, p = 0.003). STUDY LIMITATIONS: Cross-sectional design, single-center setting and potential residual confounding limit causal inference and generalizability.

conclusionAlthough not designed to assess skin disease, DAPSA may partially capture skin-related burden through its inflammatory and patient-reported components. In the absence of dedicated skin assessments, DAPSA could serve as a practical and holistic tool for initial disease activity evaluation in PsA.

Indexed as

Arthritis, PsoriaticSeverity of Illness IndexAdultCross-Sectional StudiesFemaleHumansMaleMiddle AgedQuality of LifeArthritis, psoriaticCross-sectional studiesOutcome assessment, health careSeverity of illness indexSkin diseases

Identifiers

PMID42150335

DOI10.1016/j.abd.2026.501368

PMCPMC13202544

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.